A new fund named in honour of a young Northland woman who died from a devastating lung disease at 24 will help support families affected by bronchiectasis. The Asthma and Respiratory Foundation NZ has ...

INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.

The DPP1 inhibitor did not beat placebo in this trial, leaving branded Bimzelx and Cosentyx, as well as Humira and its generics to reign across the HS market.

April 7 (Reuters) - Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial. The drug, ...

For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand ...

Insmed Inc. (NASDAQ:INSM) is one of the 10 Stocks Leaving the Market in the Dust Today. Insmed snapped a two-day losing ...

Insmed (INSM) stock is in focus as the company halts studies for lung disorder therapy brensocatib in hidradenitis ...

After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other ...

Insmed Incorporated (NASDAQ:INSM) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge ...

Ten stocks stood firmer on Monday, clocking gains and bucking a mostly pessimistic broader market, as investors gobbled up ...

Specific combinations of CT imaging features rather than individual findings alone may improve the accuracy of identifying ...

BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases. BioVersys joins forces with Hackensack Meridian Health ...